# US 2003/0229112 A1 · Combination therapy for cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0229112 A1
- Document ID: US20030229112A1
- Status: Published application
- Kind: A1
- Application number: 09/768,445
- Filed: 2001-01-24
- Published: 2003-12-11
- Earliest claimed: 2000-01-26
- Inventors: Peter J. Houghton
- Web page: https://patentgrep.com/patent/US20030229112A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for treating a human patient afflicted with cancer, is provided in which therapeutically effective amounts of temozolomide and irinotecan are administered to such a patient. Also provided is a medical kit comprising: (a) a supply of temozolomide; (b) a supply of irinotecan; and (c) printed instructions for administering temozolomide and irinotecan to a cancer patient.

## Claims

### Claim 1

A method for treating a human patient afflicted with cancer, comprising administering therapeutically effective amounts of temozolomide and irinotecan to such a patient for a time period sufficient to effect at least a partial tumor response.

### Claim 2 (depends on 1)

The method of claim 1, wherein the irinotecan is in the form of a hydrochloride salt.

### Claim 3 (depends on 1)

The method of claim 1, wherein the temozolomide and irinotecan are administered over repeated 21 day cycles, where said 21 day cycles are divided into three 1 week periods.

### Claim 4 (depends on 3)

The method of claim 3, wherein the total amount of irinotecan administered over the 21 day period ranges from 3 to 400 mg/m2 of the patient's body surface.

### Claim 5 (depends on 3)

The method of claim 3, wherein the amount of temozolomide administered over the 21 day period ranges from 50-200 mg/m2/day of the patient's surface and wherein said temozolomide is administered for 5-14 days over the 21 day period.

### Claim 6 (depends on 3)

The method of claim 3, wherein the amount of temozolomide administered over the 21 day period ranges from 50-200 mg/m2/day of the patient's surface and wherein said temozolomide is administered for 5-14 days over the 21 day period and the irinotecan is in the form of a hydrochloride salt.

### Claim 7 (depends on 3)

The method of claim 3, wherein the irinotecan is administered for 5 consecutive days at a daily dose of 10 to 40 mg/m2/day during the first week and for 5 consecutive days at a daily dose of 10 to 40 mg/m2/day during the second week, followed by the third week in which irinotecan is not administered.

### Claim 8 (depends on 7)

The method of claim 7, wherein the temozolomide is administered for 5 consecutive days at a daily dose of 100 to 200 mg/m2/day during the first week, followed by the second and third week in which temozolomide is not administered.

### Claim 9 (depends on 7)

The method of claim 7, wherein the temozolomide is administered for 5 to 7 consecutive days at a daily dose of 100 to 200 mg/m2/day during the first and third weeks of the 21 day cycle.

### Claim 10 (depends on 7)

The method of claim 7, wherein the temozolomide is administered for 5 to 7 consecutive days at a daily dose of 100 to 200 mg/m2/day during the first and second weeks of the 21 day cycle.

### Claim 11 (depends on 9)

The method of claim 9, wherein the irinotecan is in the form of a hydrochloride salt.

### Claim 12 (depends on 10)

The method of claim 10, wherein the irinotecan is in the form of a hydrochloride salt.

### Claim 13 (depends on 3)

The method of claim 3, wherein the irinotecan is administered on a single day of the 21 day cycle in an amount of from 250 to 650 mg/m2.

### Claim 14 (depends on 3)

The method of claim 3, wherein the irinotecan is administered once a week during the 21 day cycle at a dose of from 100 to 125 mg/m2.

### Claim 15 (depends on 3)

The method of claim 3 wherein the temozolomide and irinotecan are both administered on the first day of the 21 day treatment cycle.

### Claim 16 (depends on 15)

The method of claim 15, wherein the irinotecan is in the form of a hydrochloride salt.

### Claim 17 (depends on 1)

The method of claim 1, wherein the temozolomide is administered prior to the administration of the irinotecan.

### Claim 18 (depends on 3)

The method of claim 3, wherein the temozolomide and irinotecan are administered in three 21 day cycles, each cycle having a dosing period wherein the temozolomide is administered for the first five days of the 21 day cycle at a daily dose of 50 to 200 mg/m2/day, the irinotecan is administered with the temozolomide for the first 5 days of the 21 day cycle and for an additional 5 day period during the second week of the 21 day cycle at a daily dose of 10 to 40 mg/m2/day, followed by the third week in which temozolomide and irinotecan is not administered.

### Claim 19 (depends on 17)

The method of claim 17, wherein the temozolomide is administered orally and the irinotecan is administered intravenously.

### Claim 20 (depends on 1)

The method of claim 1, wherein the temozolomide and irinotecan are administered over repeated 28 day cycles.

### Claim 21 (depends on 20)

The method of claim 20, wherein the total amount of irinotecan administered over the 28 day period ranges from 3 to 400 mg/m2 of the patient's body surface.

### Claim 22 (depends on 20)

The method of claim 20, wherein the amount of temozolomide administered over the 28 day period ranges from 50-200 mg/m2/day of the patient's surface and wherein said temozolomide is administered for 5-14 days over the 28 day period.

### Claim 23 (depends on 20)

The method of claim 20, wherein the amount of temozolomide administered over the 28 day period ranges from 50-200 mg/m2/day of the patient's surface and wherein said temozolomide is administered for 5-14 days over the 28 day period and the irinotecan is in the form of a hydrochloride salt.

### Claim 24 (depends on 20)

The method of claim 20, wherein temozolomide and irinotecan are administered over a 28 day cycle, wherein the temozolomide is administered on days 1-14 of said cycle at a daily dose of 75 to 150 mg/m2/day and wherein the irinotecan is administered on day 8 of said cycle at a daily dose of 100 to 350 mg/m2/day.

### Claim 25 (depends on 24)

The method of claim 24, wherein the temozolomide is administered orally and the irinotecan is administered intravenously

### Claim 26

A medical kit for treating a cancer patient is provided, comprising:
(a) a supply of temozolomide;
(b) a supply of irinotecan; and
(c) printed instructions for administering temozolomide and irinotecan to a cancer patient.
